Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Longwing extension study of STK-001 in Dravet syndrome
ISRCTN12811235Phase 2Active, not recruiting
- Sponsor
- Stoke Therapeutics
- Start
- May 2022
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of zorevunersen in Dravet syndrome, sponsored by Stoke Therapeutics. Primary endpoints: Safety and tolerability of multiple doses of STK-001, Adverse events and 5 more. Started May 2022; status: active, not recruiting.
02
Drugs
zorevunersen
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on ISRCTN12811235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12811235.